Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04135352 · ClinicalTrials.gov registry record · Phase 1
A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001)
A Phase 1 study, sponsored by Merck Sharp & Dohme.
- Terminated
- Registry status
- Phase 1
- Development phase
- 35
- Enrollment target
NCT04135352 is a Phase 1 study that was terminated before completion, run by Merck Sharp & Dohme. The registered enrollment target is 35 participants.
The verdict
NCT04135352, a Phase 1 study, was terminated before completion, sponsored by Merck Sharp & Dohme.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 35 participants
- Enrollment target
Study Summary
The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics, and V938 shedding in participants with advanced/metastatic or recurrent malignancies who receive V938 in combination with pembrolizumab (MK-3475). The primary objective is to determine the safety and tolerability and to identify a recommended Phase 2 dose (RP2D) of V938 administered in combination with pembrolizumab.
Interventions
- DRUG 200 mg of pembrolizumab
- BIOLOGICAL V938
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 35 participants |
| Start Date | 2019-11-04 |
| Est. Completion | 2022-08-24 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04135352
The ClinicalTrials.gov registry entry for NCT04135352 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 35 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Merck Sharp & Dohme, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which 200 mg of pembrolizumab is the first listed.
NCT04135352 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT04135352 about?
NCT04135352 is a clinical study titled "A Study of Intratumoral/Intralesional Administration of V938 in Combination With Pembrolizumab (MK-3475) in Participants With Advanced/Metastatic or Recurrent Malignancies (V938-001)". The purpose of this study is to evaluate the safety, efficacy, pharmacokinetics, and V938 shedding in participants with advanced/metastatic or recurrent malignancies who receive V938 in combination with pembrolizumab (MK-3475). The primary objective is to determine the safety and tolerability and to...
What is the current status of trial NCT04135352?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 35 participants. The study started on 2019-11-04. Estimated completion is 2022-08-24.
What interventions are being tested in trial NCT04135352?
The interventions under investigation include: 200 mg of pembrolizumab (DRUG), V938 (BIOLOGICAL).
Who is sponsoring clinical trial NCT04135352?
This trial is sponsored by Merck Sharp & Dohme, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.